| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
3-O-Acetyl-α-boswellic acid targets inflammatory pathways. It inhibits LPS-induced TNF-α mRNA expression in monocytes and inhibits NF-κB activity in HEK293 cells at a concentration of 10 μM. It suppresses T cell function. It may also target prostaglandin receptors.
|
|---|---|
| ln Vitro |
In vitro, 3-O-Acetyl-α-boswellic acid exhibits potent anti-inflammatory activity. It inhibits LPS-induced TNF-α mRNA expression in monocytes and NF-κB activity in HEK293 cells when used at a concentration of 10 μM. It suppresses T cell function. It is a triterpenoid with a role as a metabolite.
|
| ln Vivo |
In vivo, 3-O-Acetyl-α-boswellic acid has anti-inflammatory activity. Its inhibition of T cell function suggests potential immunosuppressive effects. Animal studies are needed to further characterize its in vivo efficacy and safety. It has been used in traditional medicine for inflammatory conditions.
|
| Enzyme Assay |
Cell-free assays for 3-O-Acetyl-α-boswellic acid: NF-κB activity is measured using reporter gene assays or EMSA. The compound is incubated with nuclear extracts and DNA probes, and binding is measured. TNF-α mRNA expression is measured by qPCR. T cell function is assessed by measuring T cell proliferation and cytokine production in response to stimulation. The compound is incubated with T cells, and activity is measured.
|
| Cell Assay |
Cellular assays for 3-O-Acetyl-α-boswellic acid: monocytes or HEK293 cells are treated with 3-O-Acetyl-α-boswellic acid at concentrations of 0.1-100 µM for 1-24 hours, then stimulated with LPS. TNF-α mRNA expression is measured by qPCR. NF-κB activity is assessed by reporter gene assays or Western blot. T cell proliferation is measured by CFSE dilution. Cytokine production is measured by ELISA. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal studies for 3-O-Acetyl-α-boswellic acid: animal models of inflammation (e.g., carrageenan-induced paw edema, adjuvant-induced arthritis) would be used. Animals are administered 3-O-Acetyl-α-boswellic acid orally at doses of 10-100 mg/kg. Paw edema, inflammatory cytokine levels, and T cell function are assessed. Efficacy and toxicity are monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-O-Acetyl-α-boswellic acid: as a triterpenoid (MW 498.74), it may have moderate oral bioavailability. It is soluble in organic solvents. The compound is a triterpenoid metabolite. Storage: powder at -20°C for up to 3 years. It is available as an analytical standard.
|
| Toxicity/Toxicokinetics |
Toxicity of 3-O-Acetyl-α-boswellic acid: comprehensive toxicity data are limited. As a boswellic acid derivative, it is generally considered safe at moderate doses. However, high doses may cause gastrointestinal effects. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
3-α-O-acetyl-α-boswellic acid is a triterpenoid compound and a metabolite. It has been reported that 3-α-O-acetyl-α-boswellic acid is present in frankincense (Boswellia sacra) and saw-tooth frankincense (Boswellia serrata), and relevant data are available for reference.
3-O-Acetyl-α-boswellic acid is a research compound with potential applications in anti-inflammatory and immunomodulatory research. It is a boswellic acid derivative from Boswellia serrata. Its mechanism involves inhibition of NF-κB and T cell function. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C32H50O4
|
|---|---|
| Molecular Weight |
498.74
|
| Exact Mass |
498.37
|
| CAS # |
89913-60-0
|
| PubChem CID |
15181201
|
| Appearance |
White to off-white solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
563.6±50.0 °C at 760 mmHg
|
| Melting Point |
230-232℃
|
| Flash Point |
170.1±23.6 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.545
|
| LogP |
10.32
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
36
|
| Complexity |
996
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@@]12CC[C@H]3[C@@]([C@@H](CC[C@]3(C)[C@H]1CC=C1[C@@H]3CC(C)(C)CC[C@@]3(CC[C@@]21C)C)OC(=O)C)(C)C(=O)O
|
| InChi Key |
IAWGZKRQDHPFCZ-OBHGTAHRSA-N
|
| InChi Code |
InChI=1S/C32H50O4/c1-20(33)36-25-12-13-29(5)23-10-9-21-22-19-27(2,3)15-16-28(22,4)17-18-30(21,6)31(23,7)14-11-24(29)32(25,8)26(34)35/h9,22-25H,10-19H2,1-8H3,(H,34,35)/t22-,23+,24+,25+,28+,29+,30+,31+,32+/m0/s1
|
| Chemical Name |
(3R,4R,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-3-acetyloxy-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (200.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.01 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0051 mL | 10.0253 mL | 20.0505 mL | |
| 5 mM | 0.4010 mL | 2.0051 mL | 4.0101 mL | |
| 10 mM | 0.2005 mL | 1.0025 mL | 2.0051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
